Copyright
©The Author(s) 2023.
World J Clin Cases. Jan 26, 2023; 11(3): 556-565
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.556
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.556
Table 1 Comparison of scores between and within groups (mean ± SD)
Indicators | Time | Control group (n = 34) | Observation group (n = 34) | t value | P value |
APACHE II score (points) | Before treatment | 17.58 ± 3.21 | 17.62 ± 3.08 | 0.052 | 0.958 |
After treatment | 13.25 ± 2.14a | 10.11 ± 1.83a | 6.502 | 0.000 | |
MODS score (points) | Before treatment | 14.55 ± 2.53 | 14.48 ± 2.61 | 0.112 | 0.911 |
After treatment | 9.89 ± 1.67a | 8.21 ± 1.43a | 4.456 | 0.000 | |
NIHSS score (points) | Before treatment | 19.97 ± 2.07 | 20.01 ± 2.13 | 0.079 | 0.938 |
After treatment | 10.74 ± 1.74a | 8.56 ± 1.55a | 5.455 | 0.000 | |
TCM syndrome points (points) | Before treatment | 24.12 ± 2.58 | 23.97 ± 2.61 | 0.238 | 0.812 |
After treatment | 11.41 ± 1.25a | 7.85 ± 1.06a | 12.666 | 0.000 |
Table 2 Comparison of complement and immunoglobulins system indexes between and within groups (mean ± SD)
Indicators | Time | Control group (n = 34) | Observation group (n = 34) | t value | P value |
Complement C3 (g/L) | Before treatment | 1.04 ± 0.12 | 1.02 ± 0.13 | 0.659 | 0.512 |
After treatment | 1.28 ± 0.17a | 1.43 ± 0.21a | 3.237 | 0.002 | |
Complement C4 (g/L) | Before treatment | 0.22 ± 0.05 | 0.23 ± 0.04 | 0.911 | 0.366 |
After treatment | 0.31 ± 0.07a | 0.37 ± 0.09a | 3.068 | 0.003 | |
IgM (g/L) | Before treatment | 0.74 ± 0.11 | 0.73 ± 0.14 | 0.327 | 0.744 |
After treatment | 1.11 ± 0.15a | 1.36 ± 0.18a | 6.221 | 0.000 | |
IgG (g/L) | Before treatment | 9.74 ± 0.41 | 9.68 ± 0.38 | 0.626 | 0.534 |
After treatment | 10.64 ± 0.52a | 11.47 ± 0.61a | 6.038 | 0.000 |
Table 3 Comparison of intestinal mucosal barrier function indexes between groups and within groups (mean ± SD)
Indicators | Time | Control group (n = 34) | Observation group (n = 34) | t value | P value |
DAO (U/mL) | Before treatment | 3.28 ± 0.34 | 3.31 ± 0.30 | 0.386 | 0.701 |
After treatment | 4.15 ± 0.38a | 4.63 ± 0.45a | 4.752 | 0.000 | |
D-LA (mmol/L) | Before treatment | 0.18 ± 0.07 | 0.19 ± 0.06 | 0.632 | 0.529 |
After treatment | 0.27 ± 0.08a | 0.36 ± 0.10a | 4.098 | 0.000 | |
Lipopolysaccharide (ng/L) | Before treatment | 17.41 ± 4.52 | 17.35 ± 4.67 | 0.054 | 0.957 |
After treatment | 11.14 ± 2.05a | 8.21 ± 1.61a | 6.554 | 0.000 |
Table 4 Comparison of calcitonin gene-related peptide, ubiquitin carboxyl-terminal hydrolase 1, tumor necrosis factor-α, interleukin-2, interleukin-8 between and within groups (mean ± SD)
Indicators | Time | Control group (n = 34) | Observation group (n = 34) | t value | P value |
CGRP (pg/mL) | Before treatment | 21.52 ± 5.36 | 20.97 ± 5.71 | 0.409 | 0.683 |
After treatment | 28.26 ± 6.17a | 36.58 ± 6.78a | 5.292 | 0.000 | |
UCH-L1 (µg/L) | Before treatment | 0.40 ± 0.18 | 0.41 ± 0.13 | 0.263 | 0.794 |
After treatment | 0.25 ± 0.11a | 0.17 ± 0.10a | 3.138 | 0.003 | |
TNF-α (pg/mL) | Before treatment | 44.52 ± 5.89 | 42.97 ± 6.01 | 1.074 | 0.287 |
After treatment | 21.02 ± 4.15a | 14.63 ± 3.85a | 6.582 | 0.000 | |
IL-2 (pg/mL) | Before treatment | 15.89 ± 2.16 | 15.81 ± 2.24 | 0.150 | 0.881 |
After treatment | 10.13 ± 1.92a | 6.78 ± 1.52a | 7.977 | 0.000 | |
IL-8 (pg/mL) | Before treatment | 5.23 ± 0.82 | 5.18 ± 0.91 | 0.238 | 0.813 |
After treatment | 4.64 ± 0.53a | 3.47 ± 0.42a | 10.088 | 0.000 |
Table 5 Comparison of intestinal flora between groups and within groups (mean ± SD)
Indicators | Time | Control group (n = 34) | Observation group (n = 34) | t value | P value |
Bifidobacterium (× 107 CFU) | Before treatment | 9.74 ± 1.14 | 9.67 ± 1.21 | 0.246 | 0.807 |
After treatment | 11.11 ± 1.25a | 12.78 ± 1.34a | 5.314 | 0.000 | |
Lactobacillus (× 107 CFU) | Before treatment | 9.42 ± 1.14 | 9.36 ± 1.08 | 0.223 | 0.824 |
After treatment | 10.78 ± 1.27a | 12.63 ± 1.41a | 5.685 | 0.000 | |
Enterococcus (× 107 CFU) | Before treatment | 8.85 ± 1.14 | 8.79 ± 1.21 | 0.210 | 0.834 |
After treatment | 9.75 ± 1.21a | 11.41 ± 1.37a | 5.296 | 0.000 | |
Bacteroides (× 107 CFU) | Before treatment | 7.96 ± 0.21 | 8.02 ± 0.26 | 1.047 | 0.299 |
After treatment | 6.41 ± 0.17a | 6.02 ± 0.14a | 10.326 | 0.000 |
Table 6 Comparison of the incidence of gastrointestinal complications and pressure ulcers between groups, n (%)
Group | Gastrointestinal complications | Pressure ulcer | Total complications | |||
Diarrhea | Constipate | Gastrointestinal bleeding | Vomit | |||
Control group (n = 34) | 2 (5.88) | 1 (2.94) | 1 (2.94) | 3 (8.82) | 1 (2.94) | 8 (23.53) |
Observation group (n = 34) | 1 (2.94) | 0 (0.00) | 0 (0.00) | 2 (5.88) | 0 (0.00) | 3 (8.82) |
χ2 value | 2.711 | |||||
P value | 0.100 |
Table 7 Comparison of ventilator-associated pneumonia incidence, weaning success rate, hospital stay, and 28-d mortality between groups, n (%)
Group | Incidence of VAP | Offline success rate | Hospital stay (d) | 28 d case fatality rate (%) |
Control group (n = 34) | 11 (32.35) | 18 (52.94) | 20.56 ± 5.82 | 7 (20.59) |
Observation group (n = 34) | 5 (14.71) | 23 (67.65) | 16.78 ± 4.53 | 2 (5.88) |
χ2/t value | 2.942 | 1.536 | 2.989 | 3.202 |
P value | 0.086 | 0.215 | 0.004 | 0.074 |
- Citation: Gou LK, Li C. Qixue Shuangbu decoction and acupuncture combined with Western medicine in acute severe stroke patients. World J Clin Cases 2023; 11(3): 556-565
- URL: https://www.wjgnet.com/2307-8960/full/v11/i3/556.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i3.556